ArticleRevista espanola de salud publica2018
[Future prevalence evolution of the diabetes mellitus. Analysis in the Spanish case].
Article in Revista espanola de salud publica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFrequently, the projections on the prevalence of diabetes point to a scenario of continued, not encouraging, increase; however, although it could be very early to say this is a consolidated trend, the latest data gathered could show a more optimistic future. The aim in this work was to exhaustively detail the possible scenarios on the future evolution of diabetes mellitus prevalence. Each one of them was statistically tested to assess the available data and to contrast three theoretical hypotheses about the probability of the disease increase or evolution.
methodsThree possible scenarios have been proposed which have been contrasted with linear, logistic and lognormal regression models. Data was gathered from different national health surveys from 1999 to 2014.
resultsFor the linear model the prevalence would reach 8.5% in the year 2025 and it would continue to grow, with the logistic model the increase slows down and stabilizes at 8.6%, and for the lognormal model the prevalence would begin to decrease once, in 2025, 8.6% has been reached.
conclusionsA growing awareness about the need for a balanced diet or about the benefits of continued physical exercise, the different public health measures that governments begin to implement, along with biotechnological development, especially on DM 1, could be starting to show an impact on the prevalence incipient decrease of this illness.
Indexed as
Identifiers
30154399PMC11587276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.